Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Eribulin|DRUG: Gemcitabine
Sponsor: Asan Medical Center
Collaborators: Eisai Inc.|Dong-A ST Co., Ltd.|Samyang Biopharmaceuticals Corporation